New drug cocktail may reboot radioiodine in resistant thyroid cancers

NCT ID NCT04462471

First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 26 times

Summary

This early-phase trial tested whether combining two drugs, vemurafenib and copanlisib, can help radioactive iodine therapy shrink tumors in people with advanced thyroid cancer that no longer responds to standard radioiodine treatment. Only 8 participants with a specific BRAF gene mutation were enrolled. The main goal was to find a safe dose and see if the combination could restore the cancer's sensitivity to radioiodine.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for THYROID CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)

    Basking Ridge, New Jersey, 07920, United States

  • Memorial Sloan Kettering Bergen (Limited Protocol Activities)

    Montvale, New Jersey, 07645, United States

  • Memorial Sloan Kettering Cancer Center @ Commack (Limited Protocol Activities)

    Commack, New York, 11725, United States

  • Memorial Sloan Kettering Monmouth (Limited protocol activities)

    Middletown, New Jersey, 07748, United States

  • Memorial Sloan Kettering Nassau (Limited protocol activities)

    Rockville Centre, New York, 11553, United States

  • Memorial Sloan Kettering Westchester (Limited protocol activities)

    Harrison, New York, 10604, United States

  • Memorial Sloan-Kettering Cancer Center (All protocol activities)

    New York, New York, 10065, United States

Conditions

Explore the condition pages connected to this study.